Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
May 01, 2023 09:00 ET
|
Cassava Sciences, Inc.
Over 1,244 Alzheimer’s patients now enrolled in Phase 3 studies of simufilam.Completion of patient enrollment for Phase 3 program still expected Q4 2023.$187.5 Million Cash and Cash Equivalents at...
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
April 26, 2023 09:12 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, April 26, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier,...
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
February 28, 2023 09:15 ET
|
Cassava Sciences, Inc.
In Q2 2023, We Expect to Complete Patient Dosing for our Cognition Maintenance Study in Alzheimer’s disease.In Q3 2023, We Expect to Announce Results of our Cognition Maintenance Study.In Q4 2023, We...
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
February 08, 2023 09:15 ET
|
Cassava Sciences, Inc.
953 Alzheimer’s Patients Are Now Enrolled Across Phase 3 Studies Both Phase 3 Studies Have Passed the Halfway Mark for Enrollment Goal Is to Complete Enrollment for Both Phase 3 Studies by Year-End...
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
January 24, 2023 09:15 ET
|
Cassava Sciences, Inc.
ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets.47% of patients improved on ADAS-Cog over 1 year, and...
Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD
December 20, 2022 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following...
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
December 06, 2022 09:15 ET
|
Cassava Sciences, Inc.
Outside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately...
Cassava Sciences Announces Closing of $50 Million Registered Direct Offering
November 22, 2022 12:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease,...
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
November 18, 2022 13:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease,...
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
November 07, 2022 09:00 ET
|
Cassava Sciences, Inc.
– $174.7 Million Cash and Cash Equivalents at September 30, 2022 – – Over 650 Patients Now Enrolled in Phase 3 Program - – New Clinical Data for Simufilam in Alzheimer’s Disease Expected – AUSTIN,...